Stratified analysis based on age and tumor location suggested that patients over 60 years of age with high XPA expression exhibited longer survival time than those with low XPA expression (adjusted HR = 0.48, 95% CI: 0.26–0.89, P = 0.021, Fig. 4B); rectal cancer individuals who expressed higher XPA protein demonstrated favorable prognosis (HR = 0.56, 95% CI: 0.32–0.97, P = 0.037, Fig. 4C). This evidence concerns the gene XPA and neoplasm.